Meet IAG at MedInvest Cardiovascular & Nuerovascular Conference.

Meet IAG at MedInvest Cardiovascular & Nuerovascular Conference.

Meet IAG’s team at MedInvest Cardiovascular & Nuerovascular Conference.

IAG’s team will be attending MedInvest Cardiovascular & Nuerovascular Conference, 2020. Our who objective is to meet clinical stage biotech companies developing novel treatments to address patients’ needs.

Together with our venture partners, IAG’s team is focused on building a diversified portfolio of innovative life science companies at various stages of clinical development. Since 2018, we have established 13 partnerships, which include 2 blue chip pharma companies and 11 biotech and research companies. 

Collaboratively, with the best academics of our time we are building mechanisms for early visibility of study performance through our DYNAMIKA platform. When needed and at the right time, our venture partners and analysts support development of the tailored strategies for potential M&As.

‘Our portfolio companies take full advantage of our R&D expertise, operational breadth and risk-sharing partnership models’, said Dr. Olga Kubassova, CEO of IAG. 

We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets. 

More on our recent partnerships can be found here:


About IAG, Image Analysis Group

Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.


Engage with our team

Dr. Olga Kubassova, CEO:

David Chia, CCO:

Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer: